Aptus Pharma IPO
Aptus Pharma IPO Details
-
Open Date
23 Sep 2025
-
Close Date
25 Sep 2025
-
Listing Date
30 Sep 2025
- IPO Price Range
₹ 67 to ₹70
- IPO Size
₹ 13.02 Cr
- Listing Exchange
BSE SME
Aptus Pharma IPO Timeline
Aptus Pharma IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 23-Sep-25 | 0.00 | 4.78 | 1.77 | 1.92 |
| 24-Sep-25 | 0.81 | 6.16 | 5.46 | 4.29 |
| 25-Sep-25 | 1.24 | 28.75 | 31.43 | 22.27 |
Last Updated: 25 September 2025 6:46 PM by 5paisa
Aptus Pharma Limited was originally incorporated in August 2010, under the name “Aptus Pharma Private Limited,” and converted to a public company recently. The company is based out of Ahmedabad, Gujarat. Aptus Pharma is in the business of marketing and distributing finished pharmaceutical formulations. It does not own manufacturing facilities itself; instead, it relies on a contract manufacturing model — it has agreements (formal and informal) with multiple manufacturers to produce its product range.
Its product portfolio spans several therapeutic categories including anti-infectives, gastrointestinal / antacids, pain management, cardiovascular & anti-diabetics, neuro-psychiatric, nutritional & wellness, etc. These are marketed in multiple dosage forms like tablets, capsules, syrups, ointments, injectables, etc.
Established in: 2010
Managing Director: Tejash Maheshchandra Hathi
Peers:
Zota health care limited
Sunrest Lifescience Limited
Lincoln Pharmaceuticals Limited
Aptus Pharma Objectives
Raise funds for working capital requirements
Build/acquire new office premises and storage infrastructure
General corporate purposes
Aptus Pharma IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹13.02 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹13.02 Cr |
Aptus Pharma IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 4,000 | 2,68,000 |
| Retail (Max) | 2 | 4,000 | 2,80,000 |
| S-HNI (Min) | 3 | 6,000 | 4,02,000 |
| S-HNI (MAX) | 6 | 12,000 | 8,04,000 |
| B-HNI (Min) | 7 | 14,000 | 9,38,000 |
Aptus Pharma IPO Reservation
| Investors Category | Subscription (times) | Shares Offered | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 1.24 | 3,52,000 | 4,36,000 | 3.05 |
| NII (HNI) | 28.75 | 2,66,000 | 76,48,000 | 53.54 |
| Individual Investors (IND category bidding for 2 Lots) | 31.43 | 6,20,000 | 1,94,88,000 | 136.42 |
| Total** | 22.27 | 12,38,000 | 2,75,72,000 | 193.00 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (in Rs. Crores) | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 13.89 | 17.85 | 24.55 |
| EBITDA | 0.57 | 1.49 | 4.75 |
| PAT | 0.19 | 0.79 | 3.09 |
| Particulars (in Rs. Crores)] | FY23 | FY24 | FY25 |
|---|---|---|---|
| Total Assets | 6.21 | 10.02 | 21.91 |
| Share Capital | 30.0 | 30.0 | 500.0 |
| Total Borrowings | 2.21 | 5.30 | 10.35 |
| Particulars (in Rs. Crores | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net Cash Generated From / (used in) operating activities | -0.18 | -2.17 | -1.83 |
| Net Cash Generated From / (used in) investing activities | -0.35 | -0.30 | -0.54 |
| Net Cash Generated From / (used in) financing activities | 0.81 | 2.85 | 6.68 |
| Net Increase (Decrease) In Cash And Cash Equivalents | 0.27 | 0.37 | 4.29 |
Strengths
1. Diversified therapeutic product portfolio
2. Multiple dosage forms increasing reach
3. Strong recent revenue & profit growth
3. Outsourced manufacturing (lower fixed assets)
Weaknesses
1. No owned manufacturing facility – dependency risk
2. High inventory and receivables build-up
3. Likely high competition in distribution / marketing domain
4. Working capital intensive business model
Opportunities
1. Growth in pharmaceutical consumption across India
2. Expansion in newer therapeutic / wellness segments
3. Increased demand for contract / third-party pharma marketing firms
4. Potential to scale storage & logistics infrastructure
Threats
1. Regulatory changes affecting pharma distribution
2. Price controls or competition-led margin pressure
3. Risks around quality and compliance in contract manufacturing
4. Fluctuations in input costs or RM supply constraints
1. Exposure to growth in Indian pharma demand
2. Fresh issue provides capital for scale and improved infrastructure
3. Diversified product / dosage form portfolio adds resilience
4. Contract manufacturing model reduces fixed asset burden
5. Substantial recent financial performance improvement
The pharma sector in India continues to be a growth story, driven by rising healthcare needs, increasing focus on preventive care, and growth in lifestyle & wellness segments. SMEs and smaller players in the formulation distribution space can benefit from this backdrop, particularly if they efficiently manage their supply chain, maintain compliance, and keep costs under control. Aptus Pharma, despite not owning manufacturing capacity, can scale more flexibly via contract manufacturers, enabling faster expansion with lower fixed overhead. Furthermore, its plan to improve infrastructure (office, storage) can support better logistics, inventory management and possibly reduce wastage or delays. However, growth hinges on geographic diversification beyond its core region, strengthening brand/market access, and ensuring regulatory adherence. If it executes well, Aptus Pharma has scope to capture more share in India’s growing pharmaceutical markets, especially in retail / semi-urban and untapped therapeutic categories.
- Companies
- Type
- Opening On
-
Wakefit Innovations
- Mainboard
- 08th Dec
- Pre-Book
-
Corona Remedies
- Mainboard
- 08th Dec
- Pre-Book
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Aptus Pharma IPO opens from September 23, 2025 to September 25, 2025.
The size of Aptus Pharma IPO is ₹13.02 Cr.
The price band of Aptus Pharma IPO is fixed at ₹67 to ₹70 per share.
To apply for Aptus Pharma IPO, follow the steps given below:
● Login to your 5paisa account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Aptus Pharma IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of the Aptus Pharma IPO is of 4,000 shares and the investment required is ₹2,68,000.
The share allotment date of Aptus Pharma IPO is September 29, 2025.
The Aptus Pharma IPO will likely be listed on September 30, 2025.
Interactive Financial Services Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Aptus Pharma plans to utilise the raised capital from the IPO for:
● Raise funds for working capital requirements
● Build/acquire new office premises and storage infrastructure
● General corporate purposes
Aptus Pharma Contact Details
Ashutosh Buildcon, Opp. Slok - 2,
Nr. Harikrupa Logistic Park,
Aslali, Ahmedabad, Daskroi,
Ahmedabad, Gujarat, 382427
Phone: +91 76004 27827
Email: info@aptuspharma.com
Website: https://aptus-pharma.com/
Aptus Pharma IPO Register
Bigshare Services Pvt.Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Aptus Pharma IPO Lead Manager
Interactive Financial Services Ltd